TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05500547

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: US Public Health Service USPSH criteria for assessment of success of resin composite restorations
Description: US Public Health Service USPSH criteria for color match, marginal adaptation, surface texture, retention, recurrent caries and others after 1, 3, 6 and 9 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: US Public Health Service USPSH criteria for assessment of success of resin composite restorations
Description: US Public Health Service USPSH criteria for color match, marginal adaptation, surface texture, retention, recurrent caries and others after 1, 3, 6 and 9 months.
Study: NCT05926986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise. Additionally, pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: No additional treatment will be practiced to the control group.
Study: NCT05881733

Intervention type: DEVICE
Group type: OTHER
Intervention: POLARx FIT cryoballoon
Description: Patients will undergo cryoablation with the 31 mm balloon size of the POLARx FIT cryoballoon.
Study: NCT06527547

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation
Description: Transcutaneous auricular vagus nerve stimulation(taVNS) , as an emerging neuromodulation therapy, integrates China's traditional meridian and acupoint theory with transcutaneous electrical nerve stimulation technology, representing a non-invasive, simple alternative therapy. Electrical stimulation of auricular points (areas on the ear following the vagus nerve pathway) stimulates the parasympathetic system, leading to slow-wave sleep through activation of the reticular formation. Vagus nerve stimulation can also regulate sleep by altering concentrations of neurotransmitters such as gamma-aminobutyric acid (GABA), norepinephrine, and serotonin, making it a safe and effective method for treating primary sleep disorders. In rheumatoid arthritis (RA), studies have shown that vagus nerve stimulation can reduce disease activity and serum levels of inflammatory cytokines.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation
Description: Transcutaneous auricular vagus nerve stimulation(taVNS) , as an emerging neuromodulation therapy, integrates China's traditional meridian and acupoint theory with transcutaneous electrical nerve stimulation technology, representing a non-invasive, simple alternative therapy. Electrical stimulation of auricular points (areas on the ear following the vagus nerve pathway) stimulates the parasympathetic system, leading to slow-wave sleep through activation of the reticular formation. Vagus nerve stimulation can also regulate sleep by altering concentrations of neurotransmitters such as gamma-aminobutyric acid (GABA), norepinephrine, and serotonin, making it a safe and effective method for treating primary sleep disorders. In rheumatoid arthritis (RA), studies have shown that vagus nerve stimulation can reduce disease activity and serum levels of inflammatory cytokines.
Study: NCT05294367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Chloride-based Lotion
Description: Given topically

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Special Diet Therapy
Description: Consume magnesium rich foods

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Special Diet Therapy
Description: Consume magnesium rich foods

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Special Diet Therapy
Description: Consume magnesium rich foods
Study: NCT05263713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suture Closure of Linear Wounds
Description: Half of the wound is repaired with running subcuticular sutures and the other half is repaired with running horizontal mattress sutures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suture Closure of Linear Wounds
Description: Half of the wound is repaired with running subcuticular sutures and the other half is repaired with running horizontal mattress sutures.
Study: NCT06010823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PlaXtreme
Description: A robotic device capable of applying motor error enhancement forces during upper limb practice in a virtual environment. The forces stimulate the body's instinctive adaptive response, which does not require the use of cognition to correct the patients hand movement.~The device consists of a controller and specifically designed games projected on a screen requiring 3D active reaching movements. During the treatment sessions, the device will be operated by a trained occupational therapist.
Study: NCT05796167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin (Nuplazid) 34 mg oral capsules once a day for 6 weeks
Study: NCT06336161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: to compare between Ultrasound-Guided ESPB and Ultrasound-Guided CEI for postoperative pain relief in patients who underwent lumbosacral surgeries.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: to compare between Ultrasound-Guided ESPB and Ultrasound-Guided CEI for postoperative pain relief in patients who underwent lumbosacral surgeries.
Study: NCT05681169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School-based HPV-counselling and HPV-vaccination.
Description: 1. Scholl-based parental HPV-counselling~2. Scholl-based pupil HPV-counselling~3. Scholl-based HPVV
Study: NCT04765059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
Description: Randomized patients will receive oral dose of osimertinib with intravenous (IV) pemetrexed plus either IV cisplatin or IV carboplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
Description: Randomized patients will receive oral dose of placebo matching osimertinib with IV pemetrexed plus either IV cisplatin or IV carboplatin
Study: NCT06488807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory Enrichment
Description: Each participant will be equipped with an electrical odor dispenser which allowed to distribute 8 odors (grapefruit, lavender, lemon, peppermint, menthol, tangerine, green tea, and bergamot). The choice of odors was guided by (1) pleasantness of the odors, (2) presence of slight trigeminal activation in some of the odors, e.g., peppermint, (3) evaporation characteristics, so that the odors would last for the duration of the experiment, (4) technical issues mostly in terms of compatibility with the odor cartridge, (5) availability, and (6) inspiration from the previous studies.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Water will be used in the dispenser.
Study: NCT05252988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib orally once daily for 13 cycles, unless patient discontinues earlier.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Description: Colesevelam capsules orally, 2 times a day for the first month (28 days).
Study: NCT06475235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized immunoglobin G4 monoclonal antibody, 4 mL vials, via intravenous infusion (into the vein) per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized immunoglobin G4 monoclonal antibody, 4 mL vials, via intravenous infusion (into the vein) per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Anti-metabolite, 50 mL vials, via intravenous infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Alkylating agent, 5, 20, 100, 140, 180, or 250 mg capsules, taken orally per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Anti-CD20 antibody, 10 or 50 mL single-use vials, via intravenous infusion per standard of care.
Study: NCT05385718

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Participants are required to undergo a non-invasive magnetic resonance imaging (MRI) scan approximately 30 minutes in length.
Study: NCT05874219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local antibiotic spray Neomycin sulphate 165,000 IU + Bacitracin zinc 12,500 IU
Description: The intervention Sprayed 1 to 3 times /day
Study: NCT04313712

Intervention type: DRUG
Intervention: ibogaine with magnesium treatment
Description: Participants will receive magnesium sulfate intravenously and ibogaine orally.
Study: NCT05874219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin 2% ointment
Description: 10 mm of mupirocin ointment squeezed directly on to their exit sites from a 15 g tube with an outlet diameter of 5 mm
Study: NCT04792151

Intervention type: BEHAVIORAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents
Description: The Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C and UP-A) are transdiagnostic, behavioral interventions for youth with emotional disorders, including anxiety, depression, obsessive-compulsive disorders, and irritability.
Study: NCT06476184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Patients will be randomized 1:1:~* Experimental arm: Densification of the chemotherapy administration dose and dosing schedule of carboplatin-paclitaxel (carboplatin AUC 5 every 3 weeks on day 1 and paclitaxel 80 mg/m2 every week, on day 1, day 8, and day 15, with 3 week-cycles) for 3 cycles~* Standard arm: Continuation of the same 3-weekly carboplatin-paclitaxel, as administered during the neo-adjuvant chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Patients will be randomized 1:1:~* Experimental arm: Densification of the chemotherapy administration dose and dosing schedule of carboplatin-paclitaxel (carboplatin AUC 5 every 3 weeks on day 1 and paclitaxel 80 mg/m2 every week, on day 1, day 8, and day 15, with 3 week-cycles) for 3 cycles~* Standard arm: Continuation of the same 3-weekly carboplatin-paclitaxel, as administered during the neo-adjuvant chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients will be randomized 1:1:~* Experimental arm: Densification of the chemotherapy administration dose and dosing schedule of carboplatin-paclitaxel (carboplatin AUC 5 every 3 weeks on day 1 and paclitaxel 80 mg/m2 every week, on day 1, day 8, and day 15, with 3 week-cycles) for 3 cycles~* Standard arm: Continuation of the same 3-weekly carboplatin-paclitaxel, as administered during the neo-adjuvant chemotherapy
Study: NCT06291077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Changing of anticalcineurins by Belatacept

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anticalcineurins
Description: Keeping of anticalcineurins
Study: NCT06476184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Patients will be randomized 1:1:~* Experimental arm: Densification of the chemotherapy administration dose and dosing schedule of carboplatin-paclitaxel (carboplatin AUC 5 every 3 weeks on day 1 and paclitaxel 80 mg/m2 every week, on day 1, day 8, and day 15, with 3 week-cycles) for 3 cycles~* Standard arm: Continuation of the same 3-weekly carboplatin-paclitaxel, as administered during the neo-adjuvant chemotherapy
Study: NCT04695730

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active physical therapy (including both pain education and home exercises)
Description: One session (60 minutes). In this session, a physical therapist will explain and demonstrate the exercises to perform individually at home. Exercises will be performed daily. In addition, an education session will be provided, concerning pain mechanisms and management. To support patients during the treatment, a booklet will be created.~One booster session (30minutes) will be planned after 4 weeks. Patients will follow the active treatment for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active physical therapy plus manual therapy
Description: Participants in the Group 2 will receive active intervention plus 8 Pompage technique sessions (1 session/week). In these sessions (30 minutes each), Pompage technique will be performed by a physical therapist.
Study: NCT05527704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Patients assigned to the active group will be treated with 0.15 mg/kg body weight (diluted in 3 mL 0.9% NaCl) nebulized salbutamol (Ventolin®, GlaxoSmithKline, Dublin, Ireland) for 30 min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0,9% Chloride Sodium
Description: 3 mL nebulized 0.9% NaCl administered for 30 min.
Study: NCT04954469

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoVAC-1
Description: Peptide vaccination should be started as soon as possible after the screening visit.
Study: NCT01924897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Study: NCT06332053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-5007
Description: SY-5007 80 mg, Tablets, 2 discrete single doses at Day 1 and Day 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 200 mg, Capsules, Day 8-Day 18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-5007
Description: SY-5007 160 mg, Tablets, 2 discrete single doses at Day 1 and Day 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin 600 mg, Capsules, Day 8-Day 21
Study: NCT05705050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminophylline group
Description: Patients will receive 4 mg/kg aminophylline diluted in 100 ml normal saline over 20 minutes after induction of anesthesia and positioning of patients in lithotomy position.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Patients will receive 100 ml normal saline over 20 minutes after induction and lithotomy positioning.
Study: NCT05211505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WO 2707
Description: Intravaginal application once daily for 1 week, then twice per week until visit 3 (day 38).
Study: NCT05161117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality simulation app for caregiver education
Description: Using a virtual reality headset/goggles, caregivers will engage with an interactive app experience to identify and mediate fall risk hazards in the inpatient care environment. The app will present a hospital bedroom and bathroom laden with fall risks. As the caregiver progresses through the experience, the caregiver will ambulate (virtually) through the environment with the goal of identifying fall risks inherent within that inpatient setting. Fall risks will be targeted and identified using the app sighting function and after focusing on the fall risk for the allotted marking time, will self-resolve.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: online fall prevention education module
Description: Participants in both intervention and control groups will complete a 20 minute online module: Management of the Patient at Risk for Falls, through the MyLearning education platform. Most caregivers would have taken this module during competencies or orientation, but at various times. It will be taken by all participants in this study to serve as a baseline understanding of identifying and caring for patients at risk for falls. Participants will be enrolled in the module by a member of the research team, and learner transcripts will available through MyLearning education to confirm completion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online fall prevention education module
Description: Participants in both intervention and control groups will complete a 20 minute online module: Management of the Patient at Risk for Falls, through the MyLearning education platform. Most caregivers would have taken this module during competencies or orientation, but at various times. It will be taken by all participants in this study to serve as a baseline understanding of identifying and caring for patients at risk for falls. Participants will be enrolled in the module by a member of the research team, and learner transcripts will available through MyLearning education to confirm completion.
Study: NCT06100029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lavender
Description: The lavender aroma (L. angustifolia ssp. Angustifolia) is provided by Pranarom International, Ghislenghien, Belgium. Lavender aroma will be contained in a 10 ml glass bottle with a drop stopper and place the bottle within 20 cm of the patient's pillow so that the aroma can reach the patient. The entire course of treatment lasts 5 days.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: A2F bundle
Description: A: assess, prevent, and manage pain; B: both spontaneous awakening and breathing trials; C: choice of analgesia and sedation; D: delirium assessment, prevention, and management; E: early mobility and exercise; and F: family engagement/empowerment
Study: NCT05336968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide-Ketorolac-Ropivacaine
Description: Experimental for Osteoarthrosis of the Knee. One randomized injection to intraarticularly into affected knee at time of randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide-Ketorolac-Ropivacaine
Description: Experimental for Osteoarthrosis of the Knee. One randomized injection to intraarticularly into affected knee at time of randomization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide-Ketorolac-Ropivacaine
Description: Experimental for Osteoarthrosis of the Knee. One randomized injection to intraarticularly into affected knee at time of randomization
Study: NCT05709249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XLJDOD compound granule
Description: Treatment will begin within 3 months after standard adjuvant chemotherapy and compliance will be continuously monitored. XLJDOD will be taken twice a day, infused with warm water, 1 hour after lunch and dinner. One course of treatment will take 28 days in 1 month, and 2- to 3-day rest. Treatment will continue for 6 courses.
Study: NCT06100029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A2F bundle
Description: A: assess, prevent, and manage pain; B: both spontaneous awakening and breathing trials; C: choice of analgesia and sedation; D: delirium assessment, prevention, and management; E: early mobility and exercise; and F: family engagement/empowerment
Study: NCT06087068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thyroxine
Description: The treatment goal after lobectomy was to control TSH within the normal reference range (0.4-5 mU/L)
Study: NCT05709249

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (XLJDOD mimetic agent)
Description: The course of placebo in control group will be in accordance with that of XLJDOD in intervention group.
Study: NCT05606718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: dapagliflozin 10mg once daily for 3 months after randomization
Study: NCT06034704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plantar fascia self massage with a magnetic fascia ball
Description: Participants were asked to roll the magnetic fascia ball on the sole of each foot for 3 minutes each, from the metatarsal heads towards the heel, concentrating on the medial longitudinal arch. Participants were informed that more intense pressure would be more beneficial and were asked to apply pressure in a way that would not cause pain.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plantar fascia self massage with a non-magnetic fascia ball
Description: Participants were asked to roll the non-magnetic fascia ball on the sole of each foot for 3 minutes each, from the metatarsal heads towards the heel, concentrating on the medial longitudinal arch. Participants were informed that more intense pressure would be more beneficial and were asked to apply pressure in a way that would not cause pain.
Study: NCT05606718

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: guideline-directed medical therapy (GDMT)
Description: guideline-directed medical therapy (GDMT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: guideline-directed medical therapy (GDMT)
Description: guideline-directed medical therapy (GDMT)
Study: NCT06390137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frequency Specific Microcurrent
Description: The participant will receive an FSM treatment of 40 Hz on channel A and 97 Hz on channel B at 200 uamp with alternating current with a sharp square wave slope for 60 minutes with body contact points using a single towel wrapped posteriorly around the back at the level of T10 and the yellow (right side) and black (left side) leads will be attached to a second towel and wrapped anteriorly just below the abdomen and iliac crest. The TENS unit will be wrapped in an opaque bag so that the device is indistinguishable from that of the sham treatment.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham microcurrent treatment
Description: The participant will receive a sham FSM treatment with the machine off wrapped in an opaque bag for 60 minutes with body contact points using a single towel wrapped posteriorly around the back at the level of T10 and the yellow (right side) and black (left side) leads will be attached to a second towel and wrapped anteriorly just below the abdomen and iliac crest.
Study: NCT05745038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SONATA
Description: The SONATA intervention is composed of five components, network diagnostics, network engagement, opportunity creation, skill building and goal-setting, and feedback, that will be audio-recorded and held over six scheduled sessions.